• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

    11/14/24 5:18:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    SC 13G/A 1 madrigal13ga2-11142024.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    (Rule 13d-102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 2)1
     
    Madrigal Pharmaceuticals, Inc.
    (Name of Issuer)
    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)
    558868105
    (CUSIP Number)
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     ☐
    Rule 13d-1(b)
     
     ☒
    Rule 13d-1(c)
     
     ☐
    Rule 13d-1(d)
     
     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    PAULSON & CO. INC.
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☒
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    2,042,000 (See Note 1 to Item 4 below)
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    0
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    2,042,000 (See Note 1 to Item 4 below)
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    0
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    2,042,000 (See Note 1 to Item 4 below)
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    9.4%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    IA
     
     



    Item 1(a).
    Name of Issuer:
     
    Madrigal Pharmaceuticals, Inc. 
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
    Four Tower Bridge
    200 Barr Harbor Drive, Suite 200
    West Conshohocken, PA 19428

    Item 2(a).
    Name of Persons Filing:

    Paulson & Co. Inc. (the “Reporting Person”)
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    1133 Avenue of the Americas, New York, NY 10036
    Item 2(c).
    Citizenship:

    Delaware corporation
    Item 2(d).
    Title of Class of Securities:

    Common stock, $0.0001 par value per share (the “Common Stock”)
    Item 2(e).
    CUSIP Number:

    558868105
    Item 3.
    If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    /x/
    Not Applicable
    (a)
    / /
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b)
    / /
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    / /
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    / /
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    / /
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).*
    (f)
    / /
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F).
    (g)
    / /
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G).**
    (h)
    / /
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)
    / /
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
    (j)
    / /
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
    (k)
    / /
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).
     


    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer.

    (a)
    Amount beneficially owned: 2,042,000

    (b)
    Percent of class: 9.4%
    (c)            Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote: 2,042,000 (See Note 1)

    (ii)
    Shared power to vote or to direct the vote: 0

    (iii)
    Sole power to dispose or to direct the disposition of: 2,042,000 (See Note 1)

    (iv)
    Shared power to dispose or to direct the disposition of: 0
    The aggregate percentage of Common Stock reported owned by each person named herein is based upon  21,810,407 shares of Common Stock outstanding as of October 28, 2024, which is the total number of shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 31, 2024.
    Note 1: Paulson & Co. Inc. (“Paulson”) and its affiliates furnish investment advice to and manage onshore and offshore investment funds and separate managed accounts (such investment funds and accounts, the “Funds”).  In its role as investment advisor, or manager, Paulson possesses voting and/or investment power over the securities of the Issuer described in this schedule that are owned by the Funds.  All securities reported in this schedule are owned by the Funds.  Paulson disclaims beneficial ownership of such securities.
    Item 5.
    Ownership of Five Percent or Less of a Class.

    Not applicable.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    All securities reported in this schedule are owned by Paulson's advisory clients, none of which to Paulson's knowledge owns more than 5% of the class. Paulson itself disclaims beneficial ownership of all such securities.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not Applicable.
    Item 10.
    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURES
    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information with respect to it or him set forth in this statement is true, complete and correct.
    Dated: November 14, 2024
    PAULSON & CO. INC.
    By: /s/ Stuart L. Merzer 
          Stuart L. Merzer,
          General Counsel & Chief Compliance Officer
    Get the next $MDGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    2/26/2024$155.00Neutral → Sell
    B. Riley Securities
    More analyst ratings

    $MDGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:10:59 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $7,548,616 worth of shares (34,578 units at $218.31) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:09:05 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $12,128,340 worth of shares (64,350 units at $188.47) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      11/21/23 6:15:19 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

      Positive recommendation based on resmetirom's favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U.   CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of resmetirom

      6/20/25 6:30:32 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

      CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal's 2023 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate, op

      6/17/25 4:05:00 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

      CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Ma

      6/2/25 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care